Vericel (VCEL) Liabilities and Shareholders Equity (2010 - 2026)
Vericel (VCEL) reported Liabilities and Shareholders Equity of $485.6 million for Q1 2026, up 14.38% on a YoY basis from $424.6 million in Q1 2025, and little changed sequentially from $488.0 million in Q4 2025.
Vericel (VCEL) Liabilities and Shareholders Equity (2010 - 2026) Analysis & Trends
Vericel (VCEL) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $485.6 million in Q1 2026.
- For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 14.38% year-over-year to $485.6 million; the trailing twelve-month figure through Mar 2026 stood at $1.9 billion (up 14.65% YoY), and the FY2025 full-year result was $488.0 million, up 12.77% from the prior year.
- Liabilities and Shareholders Equity was little changed at $485.6 million in Q1 2026, from $488.0 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $488.0 million in Q4 2025 to a low of $240.3 million in Q1 2022.
- A 5-year average of $358.7 million and a median of $356.7 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
- Across the five-year window, Liabilities and Shareholders Equity climbed 10.3% in 2022 and jumped 34.54% in 2024, its largest moves.
- Tracing VCEL's Liabilities and Shareholders Equity over 5 years: stood at $273.0 million in 2022, then grew by 29.54% to $353.7 million in 2023, then increased by 22.36% to $432.7 million in 2024, then rose by 12.77% to $488.0 million in 2025, then fell by 0.48% to $485.6 million in 2026.
- Business Quant data shows VCEL's Liabilities and Shareholders Equity at $485.6 million in Q1 2026, $488.0 million in Q4 2025, and $453.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 311.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 78.88 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 8.55 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 39.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 26.48 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 40.87 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 811.27 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 10.03 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.25 Bn |
| 10 | Vericel | 2.30 Bn | 2.15 Bn | 49.27 Mn | 485.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 485.63 Mn |
| Dec 31, 2025 | 487.97 Mn |
| Sep 30, 2025 | 453.27 Mn |
| Jun 30, 2025 | 435.61 Mn |
| Mar 31, 2025 | 424.59 Mn |
| Dec 31, 2024 | 432.72 Mn |
| Sep 30, 2024 | 390.41 Mn |
| Jun 30, 2024 | 376.84 Mn |
| Mar 31, 2024 | 356.66 Mn |
| Dec 31, 2023 | 353.66 Mn |
| Sep 30, 2023 | 318.13 Mn |
| Jun 30, 2023 | 310.71 Mn |
| Mar 31, 2023 | 265.10 Mn |
| Dec 31, 2022 | 273.00 Mn |
| Sep 30, 2022 | 248.02 Mn |
| Jun 30, 2022 | 244.82 Mn |
| Mar 31, 2022 | 240.29 Mn |
| Dec 31, 2021 | 243.71 Mn |
| Sep 30, 2021 | 224.14 Mn |
| Jun 30, 2021 | 221.95 Mn |